Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) PT at $12.14

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $12.14.

A number of analysts have recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th. Piper Sandler reissued an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 11th. Finally, Truist Financial reduced their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th.

Institutional Trading of Sutro Biopharma

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Sutro Biopharma in the third quarter valued at $77,000. Barclays PLC lifted its holdings in Sutro Biopharma by 385.3% in the 3rd quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after buying an additional 216,757 shares in the last quarter. Geode Capital Management LLC boosted its position in Sutro Biopharma by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after buying an additional 132,015 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Sutro Biopharma by 222.0% during the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after acquiring an additional 71,844 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Sutro Biopharma by 30.7% during the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after acquiring an additional 25,416 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Down 1.5 %

STRO stock opened at $2.65 on Thursday. The company has a market cap of $218.52 million, a PE ratio of -1.65 and a beta of 1.17. The stock has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $3.73. Sutro Biopharma has a 12-month low of $2.45 and a 12-month high of $6.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.